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Abstracts / Osteoarthritis and Cartilage 23 (2015) A82eA416A402low abundance transcripts (< 5 reads per kilobase of exon model per
million mapped reads in both of the compared groups), as changes in
those transcripts are prone to overestimation. Changes in expression
levels were considered signiﬁcant if the adjusted p was < 0.05 and
remained below that threshold when leaving out one sample at a time
(sample-speciﬁc leave-one-out cross validation). The MetaCore Soft-
ware suite (Thomson & Reuters, New York) was used to assess if the
differentially expressed genes enrich terms (pathways) of the propri-
etary process network ontology. Pathway enrichment was considered
as signiﬁcant if the false-discovery-rate was < 0.10 and the enrichment
was due to > 2 different genes. The reproducibility of those changes was
assessed using a second independent dataset of the porcine model (n ¼
12 intact and n ¼ 6 ACLT). Histomorphometry was performed to
quantify changes in synovial membrane cellularity.
Results: 81 protein-coding genes and 7 pathways, including changes
related to Wnt signaling (i.e. upregulation of SFRP2), chemotaxis (i.e.
upregulation of CCL21), cell adhesion and proliferation, proteolysis (i.e.
upregulation of MMP1 and MMP2), as well as blood vessel morpho-
genesis and the regulation thereof, were reproducibly altered at 14 days
after ACLT when compared with joints that did not receive surgery.
Concomitantly the synovial membrane cellularity increased two-fold (p
< 0.001) in response to the surgical injury. Early triamcinolone injection
after ACLT signiﬁcantly altered the expression of 33 protein-coding
genes in the transcriptome-wide analysis, when compared to joints that
received ACLT without further treatment. These differentially expressed
genes signiﬁcantly enriched 3 ontology terms, all of which are related to
chemotaxis. Speciﬁcally, early triamcinolone treatment modiﬁed che-
motaxis-related changes in gene expression by inducing an upregula-
tion of ACKR4 and CXCL6, as well as a downregulation of CX3CR1,
without substantially modulating the cellularity (p ¼ 0.980).
Conclusions: The assessment of early changes within the synovial
membrane, a tissue that is involved in the pathogenesis of PTOA,
revealed potential new targets for early disease-modifying inter-
ventions, such as those related to Wnt signaling (SFRP2) or immuno-
modulation (CCL21, ACKR4). One potential agent is triamcinolone
acetonide, which altered gene expression patterns, particularly for the
chemotaxis pathway, but failed tomodulate the histological phenotype.
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DETERMINANTS OF LONG TERM TREATMENT RESPONSE FOLLOWING
INTRA-ARTICULAR STEROID THERAPY IN KNEE OA
T.W. O'Neill y, M.J. Parkes y, N. Maricar y, D.T. Felson z. y The Univ. of
Manchester, Manchester, United Kingdom; zBoston Univ., Boston, MA, USA
Purpose: Intra-articular steroids are an effective therapy in the man-
agement of pain in symptomatic knee osteoarthritis (OA). Data from
meta-analysis suggests that therapy is effective for up to 2 weeks fol-
lowing steroid injection with at least two large trials suggesting longer
term beneﬁt. An understanding of factors linked with longer term
response would help in targeting therapy at those who may most
beneﬁt. The aim of this analysis was to assess determinants of long term
(6 months) response to therapy.
Methods: 120 men and women with painful knee osteoarthritis, and
who met ACR criteria for the disease, were recruited for participation
in an open label clinical trial of intra-articular steroid therapy. Sub-
jects who took part in the study had signiﬁcant knee pain and either
grade 2 or higher knee OA on knee x-ray or evidence of OA on
arthroscopy or magnetic resonance imaging (MRI). At baseline sub-
jects completed the KOOS questionnaire, a Visual Analogue Scale for a
nominated activity (VASNA), the hospital anxiety and depression
inventory (HAD), the short form-12 questionnaire and the brief Illness
perception questionnaire (IPQ-B). They also had a contrast enhanced
MRI performed, from which the total bone marrow lesion (BML)
volume (mm3) and synovial tissue (ST) volume (mm3) were deter-
mined. Subjects received an injection of intra-articular depomedrone
(80mg). They were seen within 2 weeks of injection and response
assessed using the OARSI-OMERACT responder criteria. Those who
responded were followed by serial telephone call until their knee
pain recurred (within 20% of their baseline level of pain) or 6 months
at which point the trial was stopped. Logistic regression was used to
determine the factors associated with long term response to therapy
with the results expressed as odds ratios (OR) and 95% conﬁdence
intervals (CI).Results: The mean age of subjects who were recruited was 62.3 (SD
10.3) and 62 (51.6%) were female. The median time between baseline
and follow up scanwas 8 days (IQR 7 to 14 days). 85 (70.8%) were initial
responders and these subjects were then followed up by telephone.
After 6 months 23 (19.2%) out of the original cohort had still not
returned towithin 20% of their baseline level of knee pain. Compared to
those whose pain either did not respond, or who were initial res-
ponders and whose pain recurred within 6 months, persistent res-
ponders were less likely to be anxious OR ¼ 0.85 (95% CI 0.73 to 0.99),
depressed OR¼0.72 (95% CI 0.57 to 0.91) and to have a lower IPQ-B score
OR¼0.95 (95% CI 0.91 to 1.00). Neither pain assessed using KOOS or
VASNA, health related Quality of Life assessed by the SF12, or the MRI
parameters (BML & ST volume) predicted long term response. In a
multivariate model only depression score OR¼0.66 (95%CI 0.45, 0.96)
remained signiﬁcant.
Conclusions: In this open label study, almost one ﬁfth of men and
women with symptomatic knee osteoarthritis had long term beneﬁcial
reductions in pain following steroid therapy. Lower levels of depressive
symptoms are linked with long term response.
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INTRA-ARTICULAR DELIVERY OF KARTOGENIN-CONJUGATED
CHITOSAN NANO/MICROPARTICLES FOR CARTILAGE REGENERATION
G.-I. Im, M. Kang, J.-Y. Ko, J. Kim. Dongguk Univ. Int'l Hosp., Goyang,
Republic of Korea
Purpose: Osteoarthritis (OA), also known as degenerative arthritis or
degenerative joint disease, affects millions of people around the world.
Intra-articular (IA) drug delivery can be a useful modality in OA
treatment, delivering a drug directly to the main focus of the disease.
The therapeutic effect of IA drug depends mostly on the efﬁcacy of the
drug delivery system, due to the short retention time and rapid
clearance of soluble drugs from the joint. Kartogenin is a recently
characterized material that promotes the selective differentiation of
mesenchymal stem cells (MSCs) into chondrocytes, thus stimulating
cartilage regeneration. We developed an intra-articular (IA) drug
delivery system to treat osteoarthritis (OA) that consisted of kartoge-
nin conjugated chitosan (CHI-KGN). The aim of this study was to (1)
characterize the CHI-KGN particles for sustained release and chon-
drogenic activity in vitro, (2) evaluate the CHI-KGN particles as novel IA
drug delivery systems for IA retention and regeneration of OA joint in
vivo.
Methods: Kartogenin was conjugated with low-molecular-weight
chitosan (LMWCS) and medium-molecular-weight chitosan (MMWCS)
by covalent coupling of kartogenin to each chitosan using an ethyl(-
dimethylaminopropyl)carbodiimide (EDC)/N-hydroxysuccinimide
(NHS) catalyst. The particular drug delivery systems were prepared by
an ionic gelation of the CHI-KGN conjugate with tripolyphosphate
(TPP) anion that can interact with cationic chitosan by electrostatic
forces.
Results: Nanoparticles (NPs, 150±39 nm) or microparticles (MPs,
1.8±0.54 mm) were successfully fabricated from kartogenin conjugated-
LMWCS and -MMWCS, respectively, by an ionic gelation using TPP. The
in vitro release proﬁles of kartogenin from the particles showed sus-
tained release for 7 weeks. When the effects of the CHI-KGN NPs or CHI-
KGN MPs were evaluated on the in vitro chondrogenic differentiation of
human bone marrowMSCs (hBMMSCs), the CHI-KGN NPs and CHI-KGN
MPs induced higher expression of chondrogenic markers from cultured
hBMMSCs than unconjugated kartogenin. In particular, hBMMSCs
treated with CHI-KGN NPs exhibited more distinct chondrogenic
properties in the long-term pellet cultures than those treated with CHI-
KGN MPs. The in vivo therapeutic effects of CHI-KGN NPs or CHI-KGN
MPs were investigated using a surgically-induced OA model in rats. The
CHI-KGN MPs showed longer retention time in the knee joint than the
CHI-KGN NPs after IA injection in OA rats. The rats treated with CHI-
KGN NPs or CHI-KGN MPs by IA injection showed much less degener-
ative changes than untreated control or rats treated with unconjugated
kartogenin.
Conclusions: In conclusion, CHI-KGN NPs or CHI-KGN MPs can be
useful polymer-drug conjugates for an IA drug delivery system to treat
OA.
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VIRAL EXPRESSION OF TSG-6 CAN STIMULATE OSTEOPHYTE
FORMATION IN EXPERIMENTAL OSTEOARTHRITIS
M.G. Broeren, M.B. Bennink, O.J. Arntz, A.B. Blom, W.B. van den Berg,
F.A. van de Loo. Radboud Univ. Med. center, Nijmegen, Netherlands
Purpose: Tumor necrosis factor-inducible gene 6 (TSG-6, also named
TNFAPI6) is upregulated during experimental arthritis in mice (Geurts
et al. 2009). The therapeutic efﬁcacy of TSG-6 has been shown in
multiple animal models for rheumatoid arthritis, reducing bothinﬂammation and cartilage damage. Recent studies suggest that
inﬂammation can also play a role in early osteoarthritis (OA) patho-
genesis (Ayral et al. 2005). Therefore, TSG-6 therapy might also be an
effective treatment in inﬂammatory OA. In this study, we analyzed the
expression of TSG-6 during experimental arthritis and explored the
effects of TSG-6 gene therapy in a murine model of inﬂammatory
osteoarthritis.
Methods: TSG-6 gene expression was determined in microarrays of
collagenase-induced osteoarthritis at day 7 and day 14 after induction.
The murine TSG-6 genewas cloned in a lentiviral and adenoviral vector.
Freshly isolated bone marrow-derived dendritic cells (BMDCs) were
transduced with the lentiviral vector and subsequently differentiated
into osteoclasts on bone slices with M-CSF and RANKL. After 10 days,
bone slices were washed and stained using Coomassie Blue and bone
resorption was determined using the Leica Application Suite software.
To study the effects of TSG-6 in experimental knee osteoarthritis, mice
received two intra-articular injections of collagenase. Four days prior to
and 20 days after arthritis induction, mice were injected intra-articu-
larly with TSG-6 adenovirus. At day 7, inﬂammation was assessed using
ﬂuorescent Prosense probes. At day 42, knee joints were analyzed by X-
ray and histological assessment.
Results: TSG-6 was upregulated in collagenase-induced OA (2,6x at day
7 (P<0.05) and 2.5x at day 14 (P¼0.55)). BMDCs transduced with TSG-6
lentivirus showed strong expression of TSG-6. Bone resorption by
BMDC-derived osteoclasts was signiﬁcantly reduced (20.1% surface
erosion with control virus to 10.4%, p¼0.01), providing a possible
mechanism for the therapeutic effects in rheumatoid arthritis models.
At day 7 of collagenase-induced osteoarthritis, no difference in
inﬂammation was detected using the Prosense probes. At day 42, no
improvement on cartilage damage was seen, but X-ray analysis showed
strong osteophyte formation at the femur/tibia region in the knee joint.
Histological analysis showed that the osteophytes contained both bone
and cartilage.
Conclusions: Viral expression of TSG-6 can reduce the bone resorption
activity by BMDC-derived osteoclasts. The expression of TSG-6 by
synovial cells during experimental osteoarthritis results in the for-
mation of osteophytes. These results imply a causative role for TSG-6 in
osteophyte formation, supporting the recent ﬁnding that TSG-6 activity
is associated with radiographic progression of OA (Wisniewski et al.
2014).
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INTRA-ARTICULAR HYALURONIC ACID DELAYS TOTAL KNEE
REPLACEMENT IN PATIENTS WITH KNEE OSTEOARTHRITIS:
EVIDENCE FROM A LARGE U.S. HEALTH CLAIMS DATABASE
R. Altman y, S. Lim z, R. Steen x, V. Dasa k. yUCLA, Agua Dulce, CA, USA;
z Seikagaku, Tokyo, Japan; xBioventus Global, Durham, NC, USA;
k Louisiana State Univ., New Orleans, USA
Purpose: To evaluate the impact of one or more courses of treatment
with intraarticular (IA) hyaluronate (HA) compared to no IA HA injec-
tions on the time to total knee replacement (TKR) on patients with
osteoarthritis (OA), using a large administrative claims database.
Methods: Retrospective analysis used the IMS PharMetrics Plus claims
database of approximately 79 million patients to identify patients with
OA of the knee who received TKR within a 6 year selection window
(2007-2013). The initial OA diagnosis in the databasewas the index date
and included patients with knee OA who had continuous enrollment
fromOA diagnosis until TKR. Kaplan-Meier survival analysis was used to
measure time-to-TKR. Subsets were deﬁned by the number of courses
of treatment received, ranging from 0 (no IA HA), 1, 2, 3, 4, to 5 HA
courses. Median timewas the time (in years) at which 50% of patients in
a cohort had received TKR. Log-rank tests were used to compare dif-
ferent cohorts.
Results: The database included 182,022 patients with knee OA and TKR.
Of these, 131,673 (72.3%) patients had no HA, and 50,349 (27.7%)
received at least one course of IA HA. Age, sex, and Charlson comor-
bidity scores were similar among subsets. Of those receiving IA HA, a
total of 36,861 patients (73.2%) received 1 HA course, 8893 (17.7%)
received 2 courses, 2,783 (5.5%) received 3 courses, 1052 (2.1%) received
